METHODS AND COMPOSITIONS FOR THE TREATMENT OF COVID-19 AND ASSOCIATED RESPIRATORY DISTRESS AND MULTI-ORGAN FAILURE, SEPSIS, ACUTE RESPIRATORY DISTRESS SYNDROME, AND CARDIOVASCULAR DISEASES
Disclosed herein are methods and compositions for treatment of COVID-19 and associated sepsis, respiratory distress and organ failure, acute respiratory distress syndrome, sepsis, infection-induced organ failure, restenosis, critical limb ischemia, and vascular diseases associated with impaired endothelial regeneration, vascular repair, and vascular regeneration. In some embodiments, the methods include administering an effective amount of one or more of a) Dexamethasone, Resveratrol, N-acetylcysteine, Apocynin, Ebselen, APX-115, NOX2 inhibiting peptide, NOX2 inhibiting nucleic acid, Thienopyridine, orb) Selisistat, AG-1031, rabeprazole, phenazopyridine, roxadustat, molidustat, vadadustat, desidustat, decitabine, azacytidine, and analogues thereof, FOXM1 expressing nucleic acid, HIF1A expressing nucleic acid, SIRT1 inhibiting nucleic acid, EGLN1 inhibiting nucleic acid, or c) combination of one of a with one of b to a subject in need thereof. In some embodiments, the monotherapy or combination therapy is particularly useful for treatment of an elderly subject, and is useful to treat a subject at any age..
Medienart: |
Patent |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Europäisches Patentamt - (2023) vom: 10. Aug. Zur Gesamtaufnahme - year:2023 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
ZHAO YOUYANG [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
Sonstige Themen: |
---|
Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-08-10, Last update posted on www.tib.eu: 2023-08-23, Last updated: 2023-09-01 |
---|
Patentnummer: |
US2023248706 |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
EPA017881749 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | EPA017881749 | ||
003 | DE-627 | ||
005 | 20230901061328.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230829s2023 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)EPA017881749 | ||
035 | |a (EPA)US2023248706 | ||
035 | |a (EPA)79282823 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a ZHAO YOUYANG |e verfasserin |4 aut | |
245 | 1 | 0 | |a METHODS AND COMPOSITIONS FOR THE TREATMENT OF COVID-19 AND ASSOCIATED RESPIRATORY DISTRESS AND MULTI-ORGAN FAILURE, SEPSIS, ACUTE RESPIRATORY DISTRESS SYNDROME, AND CARDIOVASCULAR DISEASES |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: www.epo.org (no modifications made), First posted: 2023-08-10, Last update posted on www.tib.eu: 2023-08-23, Last updated: 2023-09-01 | ||
520 | |a Disclosed herein are methods and compositions for treatment of COVID-19 and associated sepsis, respiratory distress and organ failure, acute respiratory distress syndrome, sepsis, infection-induced organ failure, restenosis, critical limb ischemia, and vascular diseases associated with impaired endothelial regeneration, vascular repair, and vascular regeneration. In some embodiments, the methods include administering an effective amount of one or more of a) Dexamethasone, Resveratrol, N-acetylcysteine, Apocynin, Ebselen, APX-115, NOX2 inhibiting peptide, NOX2 inhibiting nucleic acid, Thienopyridine, orb) Selisistat, AG-1031, rabeprazole, phenazopyridine, roxadustat, molidustat, vadadustat, desidustat, decitabine, azacytidine, and analogues thereof, FOXM1 expressing nucleic acid, HIF1A expressing nucleic acid, SIRT1 inhibiting nucleic acid, EGLN1 inhibiting nucleic acid, or c) combination of one of a with one of b to a subject in need thereof. In some embodiments, the monotherapy or combination therapy is particularly useful for treatment of an elderly subject, and is useful to treat a subject at any age. | ||
650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
650 | 4 | |a che | |
650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
650 | 4 | |a 615 | |
773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 10. Aug. |
773 | 1 | 8 | |g year:2023 |g day:10 |g month:08 |
856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/79282823/publication/US2023248706A1?q=US2023248706 |z kostenfrei |3 Volltext |
912 | |a GBV_EPA | ||
936 | u | w | |j 2023 |b 10 |c 08 |
951 | |a AR | ||
952 | |j 2023 |b 10 |c 08 |